Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Nuformix (NFX)

Price 0.175p on 19-07-2024 at 16:30:01
Change 0.00p 0%
Buy 0.20p
Sell 0.15p
Buy / Sell NFX Shares
Last Trade: Sell 263,000.00 at 0.153p
Day's Volume: 701,356
Last Close: 0.175p
Open: 0.175p
ISIN: GB00BYW79Y38
Day's Range 0.00p - 0.00p
52wk Range: 0.15p - 0.44p
Market Capitalisation: £1m
VWAP: 0.171438p
Shares in Issue: 819m

Recent Trades History Nuformix (NFX)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 263,000 0.153p Ordinary
08:16:58 - 19-Jul-24
Buy* 438,356 0.1825p Ordinary
07:00:49 - 19-Jul-24

Share Price History for Nuformix

Time period:
to
Date Open High Low Close Volume

Share News for Nuformix

IN BRIEF: Nuformix shares fall despite interim loss narrowing

18th Jun 2024 18:37

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Posts no revenue in the six months ended March 31, unchanged from a year earlier. Pretax loss narrows to GBP242,529 from GBP337,622. Read More

Nuformix touts patent wins for idiopathic pulmonary fibrosis treatment

17th Jun 2024 10:37

(Alliance News) - Nuformix PLC on Monday celebrated multiple patent wins, after grants in both Europe and the US signalled further protections for its fibrosis and oncology technology. Read More

UK shareholder meetings calendar - next 7 days

12th Mar 2024 14:30

Read More

IN BRIEF: Nuformix announces subscription to raise GBP150,000

1st Mar 2024 10:31

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Announce intention to raise gross proceeds of GBP150,000 through a subscription for 75.0 million new shares at a price of 0.20 pence each. The shares will represent 9.2% of Nuformix's enlarged issued share capital. Company will use the subscription's net proceeds primarily to further advance its NXP002 programme for the inhaled treatment of idiopathic pulmonary fibrosis. Read More

IN BRIEF: Nuformix narrows annual loss as develops drug assets

3rd Jan 2024 10:16

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses. Read More

FTSE 100 Latest
Value8,155.72
Change-49.17

Login to your account

Forgot Password?

Not Registered